Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Won-Seog Kim

Won-Seog Kim

MD, PhD
Samsung Medical Center
Golidocitinib in R/R PTCL: analysis of the JACKPOT8 trial 1:07
Golidocitinib in R/R PTCL: analysis of the JACKPOT8 trial
Won-Seog Kim • 16 Jun 2023
REDIRECT results: AFM13 in patients with CD30+ R/R PTCL 1:35
REDIRECT results: AFM13 in patients with CD30+ R/R PTCL
Won-Seog Kim • 16 Jun 2023
DISTINKT trial analysis: efficacy and safety of IMC-001 for R/R ENKTL 1:11
DISTINKT trial analysis: efficacy and safety of IMC-001 for R/R ENKTL
Won-Seog Kim • 16 Jun 2023
Interim analysis of anbal-cel for R/R DLBCL 1:09
Interim analysis of anbal-cel for R/R DLBCL
Won-Seog Kim • 16 Jun 2023
Standard of care of CAR-T therapies for B-cell malignancies 1:57
Standard of care of CAR-T therapies for B-cell malignancies
Won-Seog Kim • 24 Nov 2022
IMC-001: preliminary results of novel PD-L1 inhibitor for R/R extranodal NK/T cell lymphoma 2:04
IMC-001: preliminary results of novel PD-L1 inhibitor for R/R extranodal NK/T cell lymphoma
Won-Seog Kim • 24 Nov 2022
Anbal-cel: Updated results from Phase I study of novel CD19-targeting CAR-T therapy 2:19
Anbal-cel: Updated results from Phase I study of novel CD19-targeting CAR-T therapy
Won-Seog Kim • 24 Nov 2022
The importance of circulating tumor DNA in patients with primary CNS lymphoma 1:03
The importance of circulating tumor DNA in patients with primary CNS lymphoma
Won-Seog Kim • 11 Jun 2022
Approaching NK/T-cell lymphoma 0:42
Approaching NK/T-cell lymphoma
Won-Seog Kim • 11 Jun 2022
The need for novel agents for the treatment of PTCL 0:51
The need for novel agents for the treatment of PTCL
Won-Seog Kim • 11 Jun 2022
Insights into a Phase I/II study assessing golidocitinib in PTCL 0:51
Insights into a Phase I/II study assessing golidocitinib in PTCL
Won-Seog Kim • 11 Jun 2022
Anbal-cel: a novel anti-CD19 CAR-T therapy with dual silencing of PD-1 & TIGIT for LBCL 1:12
Anbal-cel: a novel anti-CD19 CAR-T therapy with dual silencing of PD-1 & TIGIT for LBCL
Won-Seog Kim • 11 Jun 2022
JACKPOT8: DZD4205 in peripheral T-cell lymphoma 2:09
JACKPOT8: DZD4205 in peripheral T-cell lymphoma
Won-Seog Kim • 21 Jun 2021
EGR1 as a prognostic biomarker in ENKTL 1:07
EGR1 as a prognostic biomarker in ENKTL
Won-Seog Kim • 21 Jun 2021
HDACIs in treating r/r PTCL 1:11
HDACIs in treating r/r PTCL
Won-Seog Kim • 21 Jun 2021
Key misconceptions about biosimilars 1:05
Key misconceptions about biosimilars
Won-Seog Kim • 14 Jun 2017
The content of VJHemOnc is intended for healthcare professionals